Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.

View in: PubMed

subject areas

Antineoplastic Agents
Clinical Trials, Phase III as Topic
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multicenter Studies as Topic
Protein Kinase Inhibitors
Pyrazoles
Randomized Controlled Trials as Topic

authors with profiles

Richard A. Larson